The reported statements, read against the company's own industry.
What stands out
Valued far above the size of its business
Financials view
Market Capitalization
658.53MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Revenue (TTM)
41.47MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Profit Margin
-147.38%
vs Biotechnology peers
Updated Oct 28, 2026
Beta
1.08x
vs all stocks
Updated Oct 28, 2026
52-Week Change
8.03%
vs all stocks
Updated Oct 28, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Market Capitalization
658.53MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Enterprise Value
500.47MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Forward P/E
-7.45x
vs Biotechnology peers
Updated Oct 28, 2026
Price to Sales (TTM)
15.24x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 15.88×.Updated Oct 28, 2026
Price to Book (MRQ)
3.62x
vs Biotechnology peers
Updated Oct 28, 2026
Enterprise to Revenue
12.07x
vs Biotechnology peers
Updated Oct 28, 2026
Enterprise to EBITDA
-9.26x
vs Biotechnology peers
Updated Oct 28, 2026
Gross Margin
94.36%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 86.02%.Updated Oct 28, 2026
Profit Margin
-147.38%
vs Biotechnology peers
Updated Oct 28, 2026
Operating Margin
-3835.26%
vs Biotechnology peers
Updated Oct 28, 2026
Return on Assets (TTM)
-14.32%
vs Biotechnology peers
Updated Oct 28, 2026
Return on Equity (TTM)
-40.21%
vs Biotechnology peers
Updated Oct 28, 2026
Revenue (TTM)
41.47MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Revenue per Share (TTM)
0.1060USDUpdated Oct 28, 2026
Quarterly Revenue Growth
-97.60%
vs Biotechnology peers
Updated Oct 28, 2026
Gross Profit (TTM)
35.67MUSD
vs all stocks (USD)
Updated Oct 28, 2026
EBITDA (TTM)
-54.02MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Net Income (TTM)
-61.12MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Quarterly Earnings Growth (YoY)
-97.60%
vs Biotechnology peers
Updated Oct 28, 2026
Operating Cash Flow (TTM)
-64.99MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Levered Free Cash Flow (TTM)
-44.77MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 28, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 28, 2026
Revenue
49.80MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
274.00KUSDFY2025 · Dec 31, 2025
Gross Profit
49.53MUSDFY2025 · Dec 31, 2025
Operating Income
-48.91MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-50.34MUSDFY2025 · Dec 31, 2025
Net Income
-50.34MUSDFY2025 · Dec 31, 2025
EBIT
-42.00MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-41.38MUSDFY2025 · Dec 31, 2025
Research & Development
61.12MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
37.32MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
6.91MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
8.34MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.1400USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.1400USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
363.05MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
363.05MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-50.34MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-65.67MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-65.67MUSDDerived from operating cash flow minus capital expenditure. This filing charges 621K of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads -67.85M.FY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
63.33MUSDFY2025 · Dec 31, 2025
Interest Paid
8.33MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-50.34MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
621.00KUSDFY2025 · Dec 31, 2025
Stock-based Compensation
12.52MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
-42.00KUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
-30.22MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
707.00KUSDFY2025 · Dec 31, 2025
Capital Expenditures
0.00USDFY2025 · Dec 31, 2025
Purchase of Investments
-139.84MUSDFY2025 · Dec 31, 2025
Sale of Investments
252.86MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
113.02MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025
Long-term Debt Payments
-48.00MUSDFY2025 · Dec 31, 2025
Common Stock Repurchase
-572.00KUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-48.57MUSDFY2025 · Dec 31, 2025
Shares Outstanding
444.94MSharesUpdated Oct 28, 2026
Float Shares
218.99MSharesUpdated Oct 28, 2026
Shares Short
25.83MSharesUpdated Oct 28, 2026
Short Ratio
7.60days
vs all stocks
Updated Oct 28, 2026
Short % of Shares Outstanding
10.94%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 5.8%.Updated Oct 28, 2026
% Held by Insiders
1.12%
vs all stocks
Updated Oct 28, 2026
% Held by Institutions
83.93%
vs all stocks
Updated Oct 28, 2026
Total Cash (MRQ)
190.61MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Total Cash per Share (MRQ)
0.4280USDUpdated Oct 28, 2026
Total Debt (MRQ)
59.24MUSD
vs all stocks (USD)
Updated Oct 28, 2026
Total Debt to Equity (MRQ)
0.3394x
vs Biotechnology peers
Updated Oct 28, 2026
Current Ratio (MRQ)
13.37x
vs Biotechnology peers
Updated Oct 28, 2026
Book Value per Share (MRQ)
0.3920USDUpdated Oct 28, 2026
Total Assets
184.99MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
101.89MUSDFY2025 · Dec 31, 2025
Total Liabilities
77.45MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
83.09MUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
56.58MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
20.87MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
34.33MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
61.90MUSDFY2025 · Dec 31, 2025
Accounts Receivable
2.38MUSDFY2025 · Dec 31, 2025
Inventory
281.00KUSDFY2025 · Dec 31, 2025
Accounts Payable
3.08MUSDFY2025 · Dec 31, 2025
Short-term Debt
6.24MUSDFY2025 · Dec 31, 2025
Long-term Debt
56.58MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
366.00KUSDFY2025 · Dec 31, 2025
Retained Earnings
-2.02BUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
107.54MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
5.19MUSDFY2025 · Dec 31, 2025
52-Week Low
1.10USDUpdated Oct 28, 2026
52-Week High
2.68USDUpdated Oct 28, 2026
52-Week Change
8.03%
vs all stocks
Updated Oct 28, 2026
Beta
1.08x
vs all stocks
Updated Oct 28, 2026
50-Day MA
1.98USDUpdated Oct 28, 2026
200-Day MA
1.88USDUpdated Oct 28, 2026
Avg 10-Day Volume
1.80MSharesUpdated Oct 28, 2026
Avg 30-Day Volume
2.80MSharesUpdated Oct 28, 2026
Diluted EPS (TTM)
-0.1600USDUpdated Oct 28, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 15.24Revenue Growth YoY: -0.98
High gross margins eroded by operating costsNotable
Gross Margin: 0.94Profit Margin: -1.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.